文献速递妇科产科

管理伴或不伴卵巢癌女性的遗传性乳腺癌风险

Managing hereditary breast cancer risk in women with and without ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-04-25

综述讨论对卵巢癌患者进行BRCA1/2及其他乳腺癌风险基因检测,并针对BRCA1/2突变携带者依据卵巢癌分期与缓解状态制定乳腺癌监测、预防性药物和降低风险手术策略。

要点

  • 所有卵巢癌女性应进行BRCA1/2胚系基因检测。
  • 卵巢癌诊断后前几年BRCA1/2携带者乳腺癌风险相对较低。
  • 缓解超过两年后乳腺癌风险与卵巢癌复发风险相当,需重视乳腺癌监测与风险降低。

核心结论

  • 对早期卵巢癌的BRCA1/2携带者推荐定期乳腺癌监测并考虑药物和/或预防性乳房切除术降低风险。
  • 晚期未缓解者乳腺癌监测或预防无价值,但较有利晚期携带者可合理启动监测。
  • 持续缓解超过2-5年的不利晚期患者也应考虑更积极的筛查和预防策略,缓解五年后可考虑预防性乳房切除术。

研究设计与样本

  • 综述,讨论通过监测、预防性药物和降低风险手术评估与管理乳腺癌风险。

主要发现

  • 卵巢癌诊断后前几年BRCA1/2携带者乳腺癌风险相对较低,预后主要取决于卵巢癌。
  • 若缓解超过两年,乳腺癌风险与卵巢癌复发风险相当,有时超过复发风险。

关键数值与推荐

  • 当前指南推荐所有卵巢癌女性进行BRCA1/2胚系基因检测。
  • 对早期卵巢癌的BRCA1/2携带者推荐定期乳腺癌监测并考虑药物和/或预防性乳房切除术。
  • 晚期未缓解者乳腺癌监测或预防无价值。
  • 较有利晚期携带者可合理启动乳腺癌监测。
  • 持续缓解超过2-5年的不利晚期患者也应考虑更积极的筛查和预防策略。

临床怎么用

  • 所有卵巢癌女性应进行BRCA1/2胚系基因检测,并可扩展至其他高或中度乳腺癌风险基因。
  • 有乳腺癌或卵巢癌家族史但未发现突变者仍可能乳腺癌风险增高,需监测和风险降低策略。
  • BRCA1/2携带者卵巢癌诊断后需根据分期和缓解状态个体化制定乳腺癌监测与预防策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current guidelines recommend that all women with ovarian cancer undergo germline genetic testing for BRCA1/2. Increasingly, genetic testing is being performed via panels that include other genes that confer a high or moderate risk of breast cancer. In addition, many women with a family history of breast or ovarian cancer are not found to have a mutation, but may have increased risk of breast cancer for which surveillance and risk reduction strategies are indicated. This review discusses how to assess and manage an increased risk of breast cancer through surveillance, preventive medications, and risk-reducing surgery. Assessing and managing the increased risk of breast cancer in BRCA1/2 mutation carriers after a diagnosis of ovarian cancer can be challenging. For the first few years after an ovarian cancer diagnosis, BRCA1/2 mutation carriers have a relatively low risk of breast cancer, and their prognosis is largely determined by the ovarian cancer. However, if these women remain in remission after two years, the risk of breast cancer becomes comparable with, and in some cases exceeds, their risk of ovarian cancer recurrence. For these women, breast cancer surveillance and risk reduction becomes important to their overall health. Specifically, for BRCA1/2 carriers who are diagnosed with early-stage ovarian cancer, we recommend regular breast cancer surveillance and consideration of risk reduction with medication and/or prophylactic mastectomy. For women with advanced ovarian cancer who do not achieve remission, breast cancer surveillance or prophylaxis is not of value. However, among carriers with more favorable advanced disease, it is reasonable to initiate breast cancer surveillance. Patients with less favorable advanced stage disease who achieve sustained remission (>2-5years) should also consider more aggressive strategies for breast cancer screening and prevention. For mutation carriers who remain in remission after five years, prophylactic mastectomy can be considered.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Peters ML, Garber JE, Tung N, et al. Managing hereditary breast cancer risk in women with and without ovarian cancer. Gynecol Oncol. 2017. PMID: 28454658. doi:10.1016/j.ygyno.2017.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。